Role of Macrophage Polarization in Tumor Angiogenesis and Vessel Normalization. Implications for New Anticancer Therapies.

International Review of Cell and Molecular Biology

Volumn 301, Issue , 2013, Pages 1-35

  Chen, Peiwen ^a   Bonaldo, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Angiogenesis; Macrophage polarization; Tumor microenvironment; Tumor associated macrophages; Vessel normalization

Indexed keywords

ARGINASE 1; BEVACIZUMAB; CALGRANULIN A; CALGRANULIN B; CD11B ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; FORKHEAD TRANSCRIPTION FACTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; REACTIVE OXYGEN METABOLITE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; AUTOPHAGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL INFILTRATION; CELL LINEAGE; CELL MEMBRANE DEPOLARIZATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME INHIBITION; EPIGENETICS; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; LONG TERM SURVIVAL; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MONOCYTE; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALIA;

EID: 84872387034     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407704-1.00001-4     Document Type: Chapter

References (189)

1. Abraham D., Zins K., Sioud M., Lucas T., Schafer R., Stanley E.R., Aharinejad S. Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. Int. J. Cancer 2010, 126:1339-1352.
2. Abramovitch R., Dafni H., Smouha E., Benjamin L.E., Neeman M. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res. 1999, 59:5012-5016.
3. Aharinejad S., Paulus P., Sioud M., Hofmann M., Zins K., Schafer R., Stanley E.R., Abraham D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004, 64:5378-5384.
4. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
5. Augustin H.G., Koh G.Y., Thurston G., Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 2009, 10:165-177.
6. Balkwill F., Coussens L.M. Cancer: an inflammatory link. Nature 2004, 431:405-406.
7. Balli D., Ren X., Chou F.S., Cross E., Zhang Y., Kalinichenko V.V., Kalin T.V. Foxm1 transcription factor is required for macrophage migration during lung inflammation and tumor formation. Oncogene 2012, 31:3875-3888.
8. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87:3336-3343.
9. Bauer A.L., Jackson T.L., Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS. Comput. Biol. 2009, 5. e1000445.
10. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
11. Bergenfelz C., Medrek C., Ekstrom E., Jirstrom K., Janols H., Wullt M., Bredberg A., Leandersson K. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J. Immunol. 2012, 188:5448-5458.
12. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002, 196:254-265.
13. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
14. Blankenstein T., Qin Z.H., Uberla K., Muller W., Rosen H., Volk H.D., Diamantstein T. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J. Exp. Med. 1991, 173:1047-1052.
15. Bottazzi B., Polentarutti N., Acero R., Balsari A., Boraschi D., Ghezzi P., Salmona M., Mantovani A. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983, 220:210-212.
16. Bottazzi B., Walter S., Govoni D., Colotta F., Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 1992, 148:1280-1285.
17. Bouhlel M.A., Derudas B., Rigamonti E., Dievart R., Brozek J., Haulon S., Zawadzki C., Jude B., Torpier G., Marx N., Staels B., Chinetti-Gbaguidi G. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell. Metab. 2007, 6:137-143.
18. Brecht K., Weigert A., Hu J., Popp R., Fisslthaler B., Korff T., Fleming I., Geisslinger G., Brune B. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J. 2011, 25:2408-2417.
19. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
20. Burke B., Tang N., Corke K.P., Tazzyman D., Ameri K., Wells M., Lewis C.E. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J. Pathol. 2002, 196:204-212.
21. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De M.M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
22. Cejudo-Martin P., Morales-Ruiz M., Ros J., Navasa M., Fernandez-Varo G., Fuster J., Rivera F., Arroyo V., Rodes J., Jimenez W. Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology 2002, 36:1172-1179.
23. Chabot S., Jabrane-Ferrat N., Bigot K., Tabiasco J., Provost A., Golzio M., Noman M.Z., Giustiniani J., Bellard E., Brayer S., guerre-Girr M., Meggetto F., Giuriato S., Malecaze F., Galiacy S., Jais J.P., Chose O., Kadouche J., Chouaib S., Teissie J., Abitbol M., Bensussan A., Le B.P. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J. Exp. Med. 2011, 208:973-986.
24. Chan D.A., Kawahara T.L., Sutphin P.D., Chang H.Y., Chi J.T., Giaccia A.J. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009, 15:527-538.
25. Chen P., Huang Y., Bong R., Ding Y., Song N., Wang X., Song X., Luo Y. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin. Cancer Res. 2011, 17:7230-7239.
26. Chen W., Liu J., Meng J., Lu C., Li X., Wang E., Shan F. Macrophage polarization induced by neuropeptide methionine enkephalin (MENK) promotes tumoricidal responses. Cancer Immunol. Immunother. 2012, 61:1755-1768.
27. Chen W., Ma T., Shen X.N., Xia X.F., Xu G.D., Bai X.L., Liang T.B. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res. 2012, 72:1363-1372.
28. Cobleigh M.A., Langmuir V.K., Sledge G.W., Miller K.D., Haney L., Novotny W.F., Reimann J.D., Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 2003, 30:117-124.
29. Coffelt S.B., Tal A.O., Scholz A., De P.M., Patel S., Urbich C., Biswas S.K., Murdoch C., Plate K.H., Reiss Y., Lewis C.E. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 2010, 70:5270-5280.
30. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
31. Conrotto P., Valdembri D., Corso S., Serini G., Tamagnone L., Comoglio P.M., Bussolino F., Giordano S. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 2005, 105:4321-4329.
32. De P.M. Partners in crime: VEGF and IL-4 conscript tumour-promoting macrophages. J. Pathol. 2012, 227:4-7.
33. De P.M., Lewis C.E. Cancer: macrophages limit chemotherapy. Nature 2011, 472:303-304.
34. De P.M., Venneri M.A., Galli R., Sergi S.L., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
35. De B.K., Cauwenberghs S., Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr. Opin. Genet. Dev. 2011, 21:73-79.
36. Denardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., Rugo H.S., Hwang E.S., Jirstrom K., West B.L., Coussens L.M. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
37. Dineen S.P., Lynn K.D., Holloway S.E., Miller A.F., Sullivan J.P., Shames D.S., Beck A.W., Barnett C.C., Fleming J.B., Brekken R.A. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res. 2008, 68:4340-4346.
38. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 2006, 80:1183-1196.
39. Dorsch M., Hock H., Kunzendorf U., Diamantstein T., Blankenstein T. Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression. Eur. J. Immunol. 1993, 23:186-190.
40. Doulatov S., Notta F., Eppert K., Nguyen L.T., Ohashi P.S., Dick J.E. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat. Immunol. 2010, 11:585-593.
41. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
42. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
43. Eurich K., Segawa M., Toei-Shimizu S., Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J. Gastroenterol. 2009, 15:5249-5259.
44. Fang H.Y., Hughes R., Murdoch C., Coffelt S.B., Biswas S.K., Harris A.L., Johnson R.S., Imityaz H.Z., Simon M.C., Fredlund E., Greten F.R., Rius J., Lewis C.E. Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood 2009, 114:844-859.
45. Farinha P., Masoudi H., Skinnider B.F., Shumansky K., Spinelli J.J., Gill K., Klasa R., Voss N., Connors J.M., Gascoyne R.D. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106:2169-2174.
46. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De M.M., Autiero M., Wyns S., Plaisance S., Moons L., van R.N., Giacca M., Stassen J.M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
47. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat. Rev. Cancer 2008, 8:942-956.
48. Fokas E., Im J.H., Hill S., Yameen S., Stratford M., Beech J., Hackl W., Maira S.M., Bernhard E.J., McKenna W.G., Muschel R.J. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2012, 72:239-248.
49. Friggeri A., Yang Y., Banerjee S., Park Y.J., Liu G., Abraham E. HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin. Am. J. Physiol. Cell. Physiol. 2010, 299:C1267-C1276.
50. Fujiwara T., Fukushi J., Yamamoto S., Matsumoto Y., Setsu N., Oda Y., Yamada H., Okada S., Watari K., Ono M., Kuwano M., Kamura S., Iida K., Okada Y., Koga M., Iwamoto Y. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am. J. Pathol. 2011, 179:1157-1170.
51. Funada Y., Noguchi T., Kikuchi R., Takeno S., Uchida Y., Gabbert H.E. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep. 2003, 10:309-313.
52. Galli S.J., Borregaard N., Wynn T.A. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat. Immunol. 2011, 12:1035-1044.
53. Gil-Bernabe A.M., Ferjancic S., Tlalka M., Zhao L., Allen P.D., Im J.H., Watson K., Hill S.A., Amirkhosravi A., Francis J.L., Pollard J.W., Ruf W., Muschel R.J. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012, 119:3164-3175.
54. Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 2004, 114:623-633.
55. Gocheva V., Wang H.W., Gadea B.B., Shree T., Hunter K.E., Garfall A.L., Berman T., Joyce J.A. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010, 24:241-255.
56. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
57. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
58. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Jung S., Chimenti S., Landsman L., Abramovitch R., Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124:175-189.
59. Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G., Robinson S.C., Balkwill F.R. " Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 2008, 205:1261-1268.
60. Hamada I., Kato M., Yamasaki T., Iwabuchi K., Watanabe T., Yamada T., Itoyama S., Ito H., Okada K. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res. 2002, 22:4281-4284.
61. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., Rabie T., Kaden S., Grone H.J., Hammerling G.J., Arnold B., Ganss R. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
62. Han S., Arnold S.A., Sithu S.D., Mahoney E.T., Geralds J.T., Tran P., Benton R.L., Maddie M.A., D'Souza S.E., Whittemore S.R., Hagg T. Rescuing vasculature with intravenous angiopoietin-1 and alpha v beta 3 integrin peptide is protective after spinal cord injury. Brain 2010, 133:1026-1042.
63. Hanada T., Nakagawa M., Emoto A., Nomura T., Nasu N., Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int. J. Urol. 2000, 7:263-269.
64. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
65. Harris J.A., Jain S., Ren Q., Zarineh A., Liu C., Ibrahim S. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn. Pathol. 2012, 7:12.
66. Hedlund E.M., Hosaka K., Zhong Z., Cao R., Cao Y. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17505-17510.
67. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9349-9354.
68. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8:1369-1375.
69. Hiratsuka S., Watanabe A., Sakurai Y., kashi-Takamura S., Ishibashi S., Miyake K., Shibuya M., Akira S., Aburatani H., Maru Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008, 10:1349-1355.
70. Huang Y., Snuderl M., Jain R.K. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 2011, 19:1-2.
71. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
72. Inaba T., Sano H., Kawahito Y., Hla T., Akita K., Toda M., Yamashina I., Inoue M., Nakada H. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2736-2741.
73. Ishii M., Wen H., Corsa C.A., Liu T., Coelho A.L., Allen R.M., Carson W.F., Cavassani K.A., Li X., Lukacs N.W., Hogaboam C.M., Dou Y., Kunkel S.L. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 2009, 114:3244-3254.
74. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7:987-989.
75. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
76. Johansen J.S., Jensen B.V., Roslind A., Nielsen D., Price P.A. Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol. Biomarkers Prev. 2006, 15:194-202.
77. Joyce J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005, 7:513-520.
78. Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. mTOR regulation of autophagy. FEBS Lett. 2010, 584:1287-1295.
79. Kalin T.V., Ustiyan V., Kalinichenko V.V. Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. Cell Cycle 2011, 10:396-405.
80. Kashiwagi S., Tsukada K., Xu L., Miyazaki J., Kozin S.V., Tyrrell J.A., Sessa W.C., Gerweck L.E., Jain R.K., Fukumura D. Perivascular nitric oxide gradients normalize tumor vasculature. Nat. Med. 2008, 14:255-257.
81. Kawada M., Seno H., Kanda K., Nakanishi Y., Akitake R., Komekado H., Kawada K., Sakai Y., Mizoguchi E., Chiba T. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 2012, 31:3111-3123.
82. Kerber M., Reiss Y., Wickersheim A., Jugold M., Kiessling F., Heil M., Tchaikovski V., Waltenberger J., Shibuya M., Plate K.H., Machein M.R. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 2008, 68:7342-7351.
83. Klimp A.H., Hollema H., Kempinga C., van der Zee A.G., de Vries E.G., Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res. 2001, 61:7305-7309.
84. Koide N., Nishio A., Sato T., Sugiyama A., Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am. J. Gastroenterol. 2004, 99:1667-1674.
85. Kopp H.G., Ramos C.A., Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 2006, 13:175-181.
86. Koukourakis M.I., Giatromanolaki A., Kakolyris S., O'Byrne K.J., Apostolikas N., Skarlatos J., Gatter K.C., Harris A.L. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br. J. Cancer 1998, 77:1696-1703.
87. Kubota Y., Takubo K., Shimizu T., Ohno H., Kishi K., Shibuya M., Saya H., Suda T. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J. Exp. Med. 2009, 206:1089-1102.
88. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008, 118:3367-3377.
89. Kuniyasu H., Luo Y., Fujii K., Sasahira T., Moriwaka Y., Tatsumoto N., Sasaki T., Yamashita Y., Ohmori H. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver. Gut. 2010, 59:348-356.
90. Kurahara H., Takao S., Kuwahata T., Nagai T., Ding Q., Maeda K., Shinchi H., Mataki Y., Maemura K., Matsuyama T., Natsugoe S. Clinical significance of folate receptor beta-expressing tumor-associated macrophages in pancreatic cancer. Ann. Surg. Oncol. 2012, 19:2264-2271.
91. Lamagna C., urrand-Lions M., Imhof B.A. Dual role of macrophages in tumor growth and angiogenesis. J. Leukoc. Biol. 2006, 80:705-713.
92. Laubli H., Borsig L. Selectins promote tumor metastasis. Semin. Cancer Biol. 2010, 20:169-177.
93. Leek R.D., Harris A.L. Tumor-associated macrophages in breast cancer. J. Mammary Gland. Biol. Neoplasia. 2002, 7:177-189.
94. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56:4625-4629.
95. Leek R.D., Landers R.J., Harris A.L., Lewis C.E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 1999, 79:991-995.
96. Leek R.D., Hunt N.C., Landers R.J., Lewis C.E., Royds J.A., Harris A.L. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 2000, 190:430-436.
97. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
98. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193:727-740.
99. Lin E.Y., Li J.F., Gnatovskiy L., Deng Y., Zhu L., Grzesik D.A., Qian H., Xue X.N., Pollard J.W. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66:11238-11246.
100. Lin E.Y., Li J.F., Bricard G., Wang W., Deng Y., Sellers R., Porcelli S.A., Pollard J.W. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol. Oncol. 2007, 1:288-302.
101. Linde N., Lederle W., Depner S., van R.N., Gutschalk C.M., Mueller M.M. Vascular endothelial growth factor induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J. Pathol. 2012, 227:17-28.
102. Lissbrant I.F., Stattin P., Wikstrom P., Damber J.E., Egevad L., Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int. J. Oncol. 2000, 17:445-451.
103. Loberg R.D., Day L.L., Harwood J., Ying C., St John L.N., Giles R., Neeley C.K., Pienta K.J. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006, 8:578-586.
104. Loberg R.D., Ying C., Craig M., Yan L., Snyder L.A., Pienta K.J. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007, 9:556-562.
105. Locati M., Deuschle U., Massardi M.L., Martinez F.O., Sironi M., Sozzani S., Bartfai T., Mantovani A. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J. Immunol. 2002, 168:3557-3562.
106. Loges S., Schmidt T., Carmeliet P. Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin. Cancer Res. 2009, 15:3648-3653.
107. Luo Y.P., Zhou H., Krueger J., Kaplan C., Liao D., Markowitz D., Liu C., Chen T., Chuang T.H., Xiang R., Reisfeld R.A. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene 2010, 29:662-673.
108. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
109. Makitie T., Summanen P., Tarkkanen A., Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol. Vis. Sci. 2001, 42:1414-1421.
110. Mantovani A. From phagocyte diversity and activation to probiotics: back to Metchnikoff. Eur. J. Immunol. 2008, 38:3269-3273.
111. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 2010, 22:231-237.
112. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
113. Mantovani A., Allavena P., Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur. J. Cancer 2004, 40:1660-1667.
114. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006, 177:7303-7311.
115. Mayer R.J. Two steps forward in the treatment of colorectal cancer. N. Engl. J. Med. 2004, 350:2406-2408.
116. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
117. Murdoch C., Lewis C.E. Macrophage migration and gene expression in response to tumor hypoxia. Int. J. Cancer 2005, 117:701-708.
118. Murdoch C., Giannoudis A., Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
119. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
120. Myatt S.S., Lam E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 2007, 7:847-859.
121. Nakanishi Y., Nakatsuji M., Seno H., Ishizu S., kitake-Kawano R., Kanda K., Ueo T., Komekado H., Kawada M., Minami M., Chiba T. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 2011, 32:1333-1339.
122. Nakasone E.S., Askautrud H.A., Kees T., Park J.H., Plaks V., Ewald A.J., Fein M., Rasch M.G., Tan Y.X., Qiu J., Park J., Sinha P., Bissell M.J., Frengen E., Werb Z., Egeblad M. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
123. Negus R.P., Stamp G.W., Hadley J., Balkwill F.R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 1997, 150:1723-1734.
124. Nishie A., Ono M., Shono T., Fukushi J., Otsubo M., Onoue H., Ito Y., Inamura T., Ikezaki K., Fukui M., Iwaki T., Kuwano M. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res. 1999, 5:1107-1113.
125. Oguma K., Oshima H., Aoki M., Uchio R., Naka K., Nakamura S., Hirao A., Saya H., Taketo M.M., Oshima M. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J. 2008, 27:1671-1681.
126. Ohmori H., Fujii K., Sasahira T., Luo Y., Isobe M., Tatsumoto N., Kuniyasu H. Methionine-enkephalin secreted by human colorectal cancer cells suppresses T lymphocytes. Cancer Sci. 2009, 100:497-502.
127. Ohno S., Inagawa H., Dhar D.K., Fujii T., Ueda S., Tachibana M., Suzuki N., Inoue M., Soma G., Nagasue N. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 2003, 23:5015-5022.
128. Ohno S., Ohno Y., Suzuki N., Kamei T., Koike K., Inagawa H., Kohchi C., Soma G., Inoue M. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004, 24:3335-3342.
129. Oladipupo S., Hu S., Kovalski J., Yao J., Santeford A., Sohn R.E., Shohet R., Maslov K., Wang L.V., Arbeit J.M. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:13264-13269.
130. Olofsson B., Korpelainen E., Pepper M.S., Mandriota S.J., Aase K., Kumar V., Gunji Y., Jeltsch M.M., Shibuya M., Alitalo K., Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:11709-11714.
131. Onita T., Ji P.G., Xuan J.W., Sakai H., Kanetake H., Maxwell P.H., Fong G.H., Gabril M.Y., Moussa M., Chin J.L. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin. Cancer Res. 2002, 8:471-480.
132. Oosterling S.J., van der Bij G.J., Meijer G.A., Tuk C.W., van G.E., van R.N., Meijer S., van d.S., Beelen R.H., van E.M. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J. Pathol. 2005, 207:147-155.
133. Orre M., Rogers P.A. Macrophages and microvessel density in tumors of the ovary. Gynecol. Oncol. 1999, 73:47-50.
134. Pakala R., Watanabe T., Benedict C.R. Induction of endothelial cell proliferation by angiogenic factors released by activated monocytes. Cardiovasc. Radiat. Med. 2002, 3:95-101.
135. Palumbo J.S., Degen J.L. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb. Res. 2007, 120(Suppl. 2):S22-S28.
136. Paulus P., Stanley E.R., Schafer R., Abraham D., Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res. 2006, 66:4349-4356.
137. Pello O.M., De P.M., Mirolo M., Soucek L., Zammataro L., Amabile A., Doni A., Nebuloni M., Swigart L.B., Evan G.I., Mantovani A., Locati M. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012, 119:411-421.
138. Piras F., Colombari R., Minerba L., Murtas D., Floris C., Maxia C., Corbu A., Perra M.T., Sirigu P. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005, 104:1246-1254.
139. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
140. Qayum N., Im J., Stratford M.R., Bernhard E.J., McKenna W.G., Muschel R.J. Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin. Cancer Res. 2012, 18:161-169.
141. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
142. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
143. Reggiori F., Klionsky D.J. Autophagy in the eukaryotic cell. Eukaryot. Cell 2002, 1:11-21.
144. Roca H., Varsos Z.S., Sud S., Craig M.J., Ying C., Pienta K.J. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J. Biol. Chem. 2009, 284:34342-34354.
145. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., Squadrito M.L., Segura I., Li X., Knevels E., Costa S., Vinckier S., Dresselaer T., Akerud P., De M.M., Salomaki H., Phillipson M., Wyns S., Larsson E., Buysschaert I., Botling J., Himmelreich U., Van Ginderachter J.A., De P.M., Dewerchin M., Claesson-Welsh L., Carmeliet P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
146. Ryder M., Ghossein R.A., Ricarte-Filho J.C., Knauf J.A., Fagin J.A. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr. Relat. Cancer 2008, 15:1069-1074.
147. Saccani A., Schioppa T., Porta C., Biswas S.K., Nebuloni M., Vago L., Bottazzi B., Colombo M.P., Mantovani A., Sica A. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66:11432-11440.
148. Salvesen H.B., Akslen L.A. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int. J. Cancer 1999, 84:538-543.
149. Sawano A., Takahashi T., Yamaguchi S., Aonuma M., Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell. Growth Differ 1996, 7:213-221.
150. Sawano A., Iwai S., Sakurai Y., Ito M., Shitara K., Nakahata T., Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001, 97:785-791.
151. Schmid M.C., Avraamides C.J., Dippold H.C., Franco I., Foubert P., Ellies L.G., Acevedo L.M., Manglicmot J.R., Song X., Wrasidlo W., Blair S.L., Ginsberg M.H., Cheresh D.A., Hirsch E., Field S.J., Varner J.A. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011, 19:715-727.
152. Scotton C., Milliken D., Wilson J., Raju S., Balkwill F. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br. J. Cancer 2001, 85:891-897.
153. Shen Z., Kauttu T., Seppanen H., Vainionpaa S., Ye Y., Wang S., Mustonen H., Puolakkainen P. Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Med. Oncol. 2012, 29:2718-2726.
154. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., Rimoldi M., Biswas S.K., Allavena P., Mantovani A. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008, 18:349-355.
155. Siegall C.B., Schwab G., Nordan R.P., FitzGerald D.J., Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res. 1990, 50:7786-7788.
156. Sierra J.R., Corso S., Caione L., Cepero V., Conrotto P., Cignetti A., Piacibello W., Kumanogoh A., Kikutani H., Comoglio P.M., Tamagnone L., Giordano S. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J. Exp. Med. 2008, 205:1673-1685.
157. Solinas G., Schiarea S., Liguori M., Fabbri M., Pesce S., Zammataro L., Pasqualini F., Nebuloni M., Chiabrando C., Mantovani A., Allavena P. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J. Immunol. 2010, 185:642-652.
158. Squadrito M.L., De P.M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol. Aspects Med. 2011, 32:123-145.
159. Van d.V., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., Van S.C., Tugues S., Rolny C., De M.M., Dettori D., Hainaud P., Coenegrachts L., Contreres J.O., Van B.T., Cuervo H., Xiao W.H., Le H.C., Buysschaert I., Kharabi M.B., Geerts A., Schomber T., Bonnin P., Lambert V., Haustraete J., Zacchigna S., Rakic J.M., Jimenez W., Noel A., Giacca M., Colle I., Foidart J.M., Tobelem G., Morales-Ruiz M., Vilar J., Maxwell P., Vinores S.A., Carmeliet G., Dewerchin M., Claesson-Welsh L., Dupuy E., Van V.H., Christofori G., Mazzone M., Detmar M., Collen D., Carmeliet P. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.
160. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., Cheresh D.A., Johnson R.S. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
161. Subimerb C., Pinlaor S., Khuntikeo N., Leelayuwat C., Morris A., McGrath M.S., Wongkham S. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Mol. Med. Rep. 2010, 3:597-605.
162. Sunderkotter C., Goebeler M., Schulze-Osthoff K., Bhardwaj R., Sorg C. Macrophage-derived angiogenesis factors. Pharmacol. Ther. 1991, 51:195-216.
163. Szanto A., Balint B.L., Nagy Z.S., Barta E., Dezso B., Pap A., Szeles L., Poliska S., Oros M., Evans R.M., Barak Y., Schwabe J., Nagy L. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity 2010, 33:699-712.
164. Tai S.K., Chang H.C., Lan K.L., Lee C.T., Yang C.Y., Chen N.J., Chou T.Y., Tarng D.C., Hsieh S.L. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J. Immunol. 2012, 188:2464-2471.
165. Takashima S., Klagsbrun M. Inhibition of endothelial cell growth by macrophage-like U-937 cell-derived oncostatin M, leukemia inhibitory factor, and transforming growth factor beta1. J. Biol. Chem. 1996, 271:24901-24906.
166. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64:3731-3736.
167. Tsung K., Dolan J.P., Tsung Y.L., Norton J.A. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 2002, 62:5069-5075.
168. Tugues S., Honjo S., Konig C., Noguer O., Hedlund M., Botling J., Deschoemaeker S., Wenes M., Rolny C., Jahnen-Dechent W., Mazzone M., Claesson-Welsh L. Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization. Cancer Res. 2012, 72:1953-1963.
169. van der Bij G.J., Oosterling S.J., Meijer S., Beelen R.H., van E.M. The role of macrophages in tumor development. Cell. Oncol. 2005, 27:203-213.
170. van der Bij G.J., Oosterling S.J., Meijer S., Beelen R.H., van E.M. Therapeutic potential of Kupffer cells in prevention of liver metastases outgrowth. Immunobiology 2005, 210:259-265.
171. Vosseler S., Mirancea N., Bohlen P., Mueller M.M., Fusenig N.E. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 2005, 65:1294-1305.
172. Wang Y.C., He F., Feng F., Liu X.W., Dong G.Y., Qin H.Y., Hu X.B., Zheng M.H., Liang L., Feng L., Liang Y.M., Han H. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010, 70:4840-4849.
173. Watkins S.K., Egilmez N.K., Suttles J., Stout R.D. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J. Immunol. 2007, 178:1357-1362.
174. Weichhart T., Saemann M.D. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann. Rheum. Dis. 2008, 67(Suppl. 3):iii70-iii74.
175. Weinmann M., Jendrossek V., Handrick R., Guner D., Goecke B., Belka C. Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death pathway in a FADD/caspase-8 independent manner. Oncogene 2004, 23:3757-3769.
176. Weisshardt P., Trarbach T., Durig J., Paul A., Reis H., Tilki D., Miroschnik I., Ergun S., Klein D. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem. Cell Biol. 2012, 137:391-401.
177. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di T.E., Munn L.L., Jain R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
178. Wu H., Xu J.B., He Y.L., Peng J.J., Zhang X.H., Chen C.Q., Li W., Cai S.R. Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J. Surg. Oncol. 2012, 106:462-468.
179. Xia J.T., Wang H., Liang L.J., Peng B.G., Wu Z.F., Chen L.Z., Xue L., Li Z., Li W. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas 2012, 41:629-635.
180. Xia L., Huang W., Tian D., Zhu H., Zhang Y., Hu H., Fan D., Nie Y., Wu K. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J. Hepatol. 2012, 57:600-612.
181. Xu Y., Jagannath C., Liu X.D., Sharafkhaneh A., Kolodziejska K.E., Eissa N.T. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 2007, 27:135-144.
182. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349:427-434.
183. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
184. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., Carbone D.P., Matrisian L.M., Richmond A., Lin P.C., Moses H.L. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
185. Zhang W., Zhu X.D., Sun H.C., Xiong Y.Q., Zhuang P.Y., Xu H.X., Kong L.Q., Wang L., Wu W.Z., Tang Z.Y. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 2010, 16:3420-3430.
186. Zhang L., Dong Y., Dong Y., Cheng J., Du J. Role of integrin-beta3 protein in macrophage polarization and regeneration of injured muscle. J. Biol. Chem. 2012, 287:6177-6186.
187. Zhang Y., Morgan M.J., Chen K., Choksi S., Liu Z.G. Induction of autophagy is essential for monocyte-macrophage differentiation. Blood 2012, 119:2895-2905.
188. Zhu X.D., Zhang J.B., Zhuang P.Y., Zhu H.G., Zhang W., Xiong Y.Q., Wu W.Z., Wang L., Tang Z.Y., Sun H.C. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 2008, 26:2707-2716.
189. Zudaire E., Martinez A., Cuttitta F. Adrenomedullin and cancer. Regul. Pept. 2003, 112:175-183.